Chan S, et al. - Researchers conducted this randomized clinical trial to ascertain the efficacy of omalizumab (anti-IgE medication) in treating severe atopic dermatitis in children. Using the intention-to-treat principle, statistical analysis has been conducted. A total of 62 children, mean [SD] age, 10.3 [4.2] years, were randomized to either omalizumab (n = 30) or placebo (n = 32). In the omalizumab group, a significant reduction in eczema severity was noted compared with placebo after adjustment for the baseline objective Scoring Atopic Dermatitis index, age, and IgE level. Such improvement took place within the omalizumab group in the context of significantly potent topical corticosteroid sparing. This research presents evidence that anti-IgE therapy may play a role in the management of severe atopic dermatitis in pediatrics.